Armata AP-SA02 shows promise for SAB in Phase IIa trial, underscoring growing potential of phage therapy: GlobalData Read more
Antibacterial Resistance Leadership Group (ARLG) begins clinical trial of phage therapy for cystic fibrosis Read more